Tumor Immunology and Cancer Vaccines

作者: Shawn M. Jensen , Bernard A. Fox

DOI: 10.1007/0-387-27545-2_13

关键词: AntibodyMedicineIL-2 receptorCancer researchCancer vaccinePerforinTumor necrosis factor alphaFludarabineAdoptive cell transferCD8

摘要: From our perspective a great deal has changed in the past few years. We now appreciate that tumor-specific T cells have at least triad of properties (perforin, IFN-γ, and TNF) they can utilize to mediate tumor regression. also basic understanding vitro methods polarize primed towards “therapeutic” type 1 cytokine profile (IFN-γ TNF). Additionally, combining vaccination time when host are undergoing homeostasis-driven proliferation been shown dramatically increase frequency generated by host. The discovery CD25+CD4+ regulatory sites success adoptive transfer CD4 CD8+ TIL with non myeloablative conditioning regimen includes fludarabine, drug preferentially decimates CD4+ cells, likely be related. availability antibodies or ligands block negative signals (CTLA4) provide costimulatory (4-1BB, OX40) will extended initiated soon. next several years should prove particularly informative as trials incorporating combinations strategies make their way clinic.

参考文章(280)
Ethan M. Shevach, Rebecca S. McHugh, Angela M. Thornton, Ciriaco Piccirillo, Kannan Natarajan, David H. Margulies, Control of autoimmunity by regulatory T cells. Advances in Experimental Medicine and Biology. ,vol. 490, pp. 21- 32 ,(2001) , 10.1007/978-1-4615-1243-1_3
L. Nathanson, B. Mukherji, D. A. Clark, Studies of humoral and cell-mediated immunity in human melanoma. Yale Journal of Biology and Medicine. ,vol. 46, pp. 681- 692 ,(1973)
Mark L. Saxton, Dan L. Longo, Holly E. Wetzel, Henry Tribble, W. Gregory Alvord, Larry W. Kwak, Arnold S. Leonard, Claudio Dansky Ullmann, Brendan D. Curti, Augusto C. Ochoa, Adoptive Transfer of Anti-CD3–Activated CD4+ T Cells Plus Cyclophosphamide and Liposome-Encapsulated Interleukin-2 Cure Murine MC-38 and 3LL Tumors and Establish Tumor-Specific Immunity Blood. ,vol. 89, pp. 2529- 2536 ,(1997) , 10.1182/BLOOD.V89.7.2529
T. L. Whiteside, N. L. Vujanovic, R. B. Herberman, Natural Killer Cells and Tumor Therapy Specificity, Function, and Development of NK Cells. ,vol. 230, pp. 221- 244 ,(1998) , 10.1007/978-3-642-46859-9_13
Jens Dannull, Johannes Vieweg, Donna Niedzwiecki, Eli Gilboa, Axel Heiser, Scott Pruitt, Donna Yancey, John Madden, Doris Coleman, Zhen Su, Immunological and Clinical Responses in Metastatic Renal Cancer Patients Vaccinated with Tumor RNA-transfected Dendritic Cells Cancer Research. ,vol. 63, pp. 2127- 2133 ,(2003)
R. B. Herberman, N. L. Vujanovic, H. Hirabayashi, Wen-Chang Lin, S. Watkins, T. L. Whiteside, S. Yasumura, Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. Journal of Immunology. ,vol. 154, pp. 281- 289 ,(1995)
H Fujiwara, Y Kohno, T Hamaoka, S Murakami, H Yagi, S Sugihara, T Tsujimura, O Tarutani, T Yoshioka, Y Izumi, Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. I. Requirement of Lyt-1 dull L3T4 bright normal T cells for the induction of thyroiditis. Journal of Immunology. ,vol. 141, pp. 105- 113 ,(1988)
Hong-Ming Hu, Hauke Winter, Jun Ma, Michael Croft, Walter J. Urba, Bernard A. Fox, CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. Journal of Immunology. ,vol. 169, pp. 4897- 4904 ,(2002) , 10.4049/JIMMUNOL.169.9.4897